Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TSE advisory committee

This article was originally published in The Gray Sheet

Executive Summary

Upcoming Feb. 20 Transmissible Spongiform Encephalopathies advisory committee meeting will address implementation of the final guidance on preventive measures to reduce the possible risk of transmission of CJD and vCJD disease by blood and blood products and the document's ramifications on the blood supply. The guidance was issued in January 2002. Also on the agenda is a discussion of labeling claims for TSE agent clearance in plasma derivatives...

You may also be interested in...



Execs On The Move: New R&D Chief Promotion At HAL Allergy; Two C-Level Appointments At Starkey

HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Flu Vaccine Leader Sanofi Joins Fight Against COVID-19

As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.

UsernamePublicRestriction

Register

MT017814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel